Fisher & Paykel Healthcare Corporation Limited · NZX:FPH

Fisher & Paykel Healthcare — Shareholder Meeting (2002)

16 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2002

  1. Slide 1: Fisher & Paykel Healthcare

    =A Fisher&Paykel ~~ HEALTHCARE HEALTHCARE

  2. Slide 2: First Quarter FY03

    First Quarter FY03 • Net earnings NZ$30.4 million • Gross profit 68.6% up 1.6 percentage points from March quarter • Operating margin 36.5% • Core product revenues up 10% in US$ against Q1 last year

  3. Slide 3: Sales by Product

    Sales by Product Neonatal/ Patient Distributed Q1 FY 03 5% Warming 5% OSA/CPAP Respiratory 40% Humidification 50%

  4. Slide 4: Sales by Region

    Sales by Region New Zealand Australia 2% Other Q1 FY 03 9% 3% Asia 10% North America 50% Europe 26%

  5. Slide 5: Obstructive Sleep Apnea

    | 7 Obstructive Sleep Apnea HEALTHCARE

  6. Slide 6: Obstructive Sleep Apnea

    Obstructive Sleep Apnea • Revenue +18% • HC221 Volume up 45% • Patented ambient tracking • Flow generator revenues exceed CPAP humidifiers for first time HC221 Integrated • Improved Medicare reimbursement Flow Generator- Humidifier

  7. Slide 7: Obstructive Sleep Apnea

    Obstructive Sleep Apnea Aclaim 2 Mask Oracle Mask

  8. Slide 8: Obstructive Sleep Apnea Revenue in US$

    Obstructive Sleep Apnea 35 Revenue in US$ 30 25 20 US$M 15 10 5 0 FY 1999 FY 2000 FY 2001 FY 2002

  9. Slide 9: Respiratory Humidification

    Respiratory Humidification

  10. Slide 10: Respiratory Humidification

    Respiratory Humidification • Revenue +4% • 20% volume growth in consumables • Revenue growth in US +9% on prior year MR850 humidifier

  11. Slide 11: Respiratory Humidification

    Respiratory Humidification Neonatal breathing circuits

  12. Slide 12: Respiratory Humidification Revenue in US$

    Respiratory Humidification 50 Revenue in US$ 45 40 35 30 US$M 25 20 15 10 5 0 FY 1999 FY 2000 FY 2001 FY 2002

  13. Slide 13: Neonatal and Patient Warming

    Neonatal and Patient Warming • Revenue +23% • Continued gains in US • Large tender secured in Latin America – Q2 delivery

  14. Slide 14: Neonatal and Patient Warming Revenue in US$

    Neonatal and Patient Warming 6 Revenue in US$ 5 4 US$M 3 2 1 0 FY 1999 FY 2000 FY 2001 FY 2002

  15. Slide 15: Outlook

    Outlook • Continued growth opportunities • New and complementary products • New applications e.g. COPD • Increasing international presence

  16. Slide 16: Fisher & Paykel Healthcare

    = Fisher& Paykel R= HEALTHCARE HEALTHCARE

Fisher & Paykel Healthcare — Shareholder Meeting (2002) on 6ix